US Pharm. 2010;35(12):100. 

The FDA requested that manufacturers add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, which are used primarily to treat men with prostate cancer. The warnings would alert patients and their health care professionals to the potential risk of heart disease and diabetes in men treated with these medications. In May, the FDA reported that patients receiving GnRH agonists were at a small increased risk for diabetes, heart attack, stroke, and sudden death. The new labels will include updates about these potential risks in the Warnings and Precautions sections.